Aptamers Market

Aptamer Group (UK), Raptamer Discovery Group (US) and SomaLogic Inc. (US) are Leading Players in the Aptamers Market

The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market. On the other hand, low market acceptance as compared to antibodies is likely to restrain the market growth while shortage of skilled & trained professionals may challenge market growth to a certain extent.

The prominent players operating in this market include Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc., (US), Aptamer Sciences, Inc. (South Korea), Aptagen, LLC (US), Maravai Lifesciences (US), Kaneka Corporation (Japan), NeoVentures Biotechnology Inc. (Canada), Aptus Biotech (Spain), Base Pair Biotechnologies (US), AMSBIO (UK), Novaptech (France), Bio-Techne (US), Aptitude Medical Systems Inc (US), RayBiotech (Georgia), Alpha Diagnostic International, Inc. (US), Creative Biolabs (US), Creative Biogene (US), Vivonics Inc. (US), IBA Lifesciences GmbH (Germany), Aptabharat Innovations Pvt. Ltd (India), Profacgen (US), Mediven (Malaysia), Pure Biologics (Poland), and Oak BioSciences, Inc. (Canada). These players adopted the strategies of partnerships, agreements, and acquisitions to expand their presence in the global aptamers market.

To know about the assumptions considered for the study download the pdf brochure

Aptamer Group (UK) has developed a cutting edge Optimer technology, which is used to offer aptamer-based solutions in the market. This unique technology has enabled the company to strengthen its position in the market. The company focuses on expanding its reach into diagnostic and therapeutic applications. The company is developing Optimer therapeutics for treating myeloid cancer, renal disease, and hematological cancer. In the last three years, the company has focused on collaborations and agreements to expand its geographic reach and the capabilities of Optimer technology in therapeutics. It recently collaborated with various diagnostic and pharmaceutical companies to determine the potential for aptamers as therapeutic agents and in diagnostics. This has enabled the company to increase its foothold in the market.

Raptamer Discovery Group (US) has focused on developing next-generation aptamers for diagnostic and therapeutic applications. The company employs Raptamer technology for developing these aptamers. The company has a strong customer base including pharmaceutical companies and academic & research institutes across the globe. The company has received funding for developing aptamer-based therapeutic from various government institutes such as National Aeronautics and Space Agency (NASA) and the National Institutes of Health (NIH). This has provided the company a gateway to expand its horizon into therapeutics development applications.

SomaLogic Inc. (US) is one of the leading players in aptamer market. The company has strived to offer products and services for therapeutics development, diagnostics, and research. This has enabled the company to secure a strong foothold in the market. Its contribution to the aptamers market through mergers, collaborations, and product launches has made SomaLogic a prominent player in this market. Additionally, the company has received funding from various investors for commercializing technology platform. These strategies have enabled the company to maintain its leadership position in the market.

Related Reports:

Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) - Global Forecast to 2026

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Report Code
BT 3550
RI Published ON
Choose License Type
Request Customization
Speak to Analyst
Speak to Analyst
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
  • What are the Known and Unknown Adjacencies Impacting the Aptamers Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
©2022 MarketsandMarkets Research Private Ltd. All rights reserved